StockData
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. (MRKR) stock

MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.87−0.03 (-3.33%)

Close on Nov 13, 2026Market cap $14.51MP/E –Yield –

Marker Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Marker Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.81M, down 44.5% year over year. For fiscal 2025 it was $11.80M, down 12.4% from the year before. Over ten years it grew 21.3% a year on average. The highest annual figure on record is $27.79M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.80M-12.4%
FY2024Dec 31, 2024$13.47M+29.3%
FY2023Dec 31, 2023$10.42M-13.0%
FY2022Dec 31, 2022$11.97M-56.9%
FY2021Dec 31, 2021$27.79M+47.2%
FY2020Dec 31, 2020$18.88M+47.9%
FY2019Dec 31, 2019$12.76M+60.5%
FY2018Dec 31, 2018$7.95M+51.5%
FY2017Dec 31, 2017$5.25M+38.2%
FY2016Dec 31, 2016$3.80M+122.1%
FY2015Dec 31, 2015$1.71M+805.4%
FY2014Dec 31, 2014$189.00K-72.9%
FY2013Dec 31, 2013$697.63K-34.0%
FY2012Dec 31, 2012$1.06M+419.0%
FY2011Dec 31, 2011$203.73K-29.8%
FY2010Dec 31, 2010$290.05K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.48M-64.7%
Q1 FY2026Mar 31, 2026$2.84M-9.3%
Q4 FY2025Dec 31, 2025$2.14M-57.9%
Q3 FY2025Sep 30, 2025$2.35M-32.4%
Q2 FY2025Jun 30, 2025$4.18M+78.9%
Q1 FY2025Mar 31, 2025$3.14M+21.8%
Q4 FY2024Dec 31, 2024$5.09M+94.3%
Q3 FY2024Sep 30, 2024$3.47M+69.7%
Q2 FY2024Jun 30, 2024$2.34M-1.8%
Q1 FY2024Mar 31, 2024$2.58M-23.7%
Q4 FY2023Dec 31, 2023$2.62M+19.9%
Q3 FY2023Sep 30, 2023$2.04M-43.1%
Q2 FY2023Jun 30, 2023$2.38M-18.7%
Q1 FY2023Mar 31, 2023$3.38M-51.9%
Q4 FY2022Dec 31, 2022$2.18M-72.8%
Q3 FY2022Sep 30, 2022$3.59M-47.1%
Q2 FY2022Jun 30, 2022$2.92M-60.2%
Q1 FY2022Mar 31, 2022$7.03M+24.5%
Q4 FY2021Dec 31, 2021$8.02M+34.0%
Q3 FY2021Sep 30, 2021$6.78M+41.2%
Q2 FY2021Jun 30, 2021$7.35M+71.8%
Q1 FY2021Mar 31, 2021$5.64M+47.9%
Q4 FY2020Dec 31, 2020$5.98M+63.4%
Q3 FY2020Sep 30, 2020$4.80M+54.0%
Q2 FY2020Jun 30, 2020$4.28M+35.7%
Q1 FY2020Mar 31, 2020$3.82M+34.7%
Q4 FY2019Dec 31, 2019$3.66M+100.4%
Q3 FY2019Sep 30, 2019$3.12M+95.0%
Q2 FY2019Jun 30, 2019$3.15M+119.6%
Q1 FY2019Mar 31, 2019$2.83M+74.5%
Q2 FY2018Jun 30, 2018$1.83M+51.9%
Q1 FY2018Mar 31, 2018$1.60M+61.7%
Q4 FY2017Dec 31, 2017$1.44M+214.3%
Q3 FY2017Sep 30, 2017$1.62M+46.3%
Q2 FY2017Jun 30, 2017$1.20M-3.6%
Q1 FY2017Mar 31, 2017$989.09K–
Q4 FY2016Dec 31, 2016$456.79K–
Q3 FY2016Sep 30, 2016$1.11M–
Q2 FY2016Jun 30, 2016$1.25M–

More Marker Therapeutics figures

See a number that looks wrong?